➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Harvard Business School
Medtronic
Colorcon
AstraZeneca

Last Updated: August 9, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FOSAPREPITANT

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Fosaprepitant

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00619359 Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017) Completed Merck Sharp & Dohme Corp. Phase 3 2008-02-01 The purpose of this study is to examine the safety, tolerability, and efficacy of MK0517 to prevent Chemotherapy-Induced Nausea and Vomiting (CINV) associated with Cisplatin chemotherapy.
NCT00818259 A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134) Terminated Merck Sharp & Dohme Corp. Phase 1 2009-02-01 This study will determine the appropriate dosing regimen of aprepitant and fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric participants from 0 months to 17 years of age.
NCT00895245 Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy Terminated National Cancer Institute (NCI) Phase 2 2009-02-01 RATIONALE: Fosaprepitant dimeglumine, palonosetron hydrochloride, and dexamethasone may help lessen or prevent nausea and vomiting caused by cisplatin in patients with head and neck cancer undergoing chemotherapy and radiation therapy. PURPOSE: This phase II trial is studying how well fosaprepitant dimeglumine together with palonosetron hydrochloride and dexamethasone works in preventing nausea and vomiting caused by cisplatin in patients with stage III or stage IV head and neck cancer undergoing chemotherapy and radiation therapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Fosaprepitant

Condition Name

Condition Name for Fosaprepitant
Intervention Trials
Chemotherapy-induced Nausea and Vomiting 10
Vomiting 4
Nausea 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Fosaprepitant
Intervention Trials
Vomiting 24
Nausea 15
Postoperative Nausea and Vomiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Fosaprepitant

Trials by Country

Trials by Country for Fosaprepitant
Location Trials
United States 22
Japan 4
Brazil 2
Denmark 1
Australia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Fosaprepitant
Location Trials
California 4
New York 2
Missouri 2
Indiana 2
Texas 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Fosaprepitant

Clinical Trial Phase

Clinical Trial Phase for Fosaprepitant
Clinical Trial Phase Trials
Phase 4 5
Phase 3 7
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Fosaprepitant
Clinical Trial Phase Trials
Completed 11
Not yet recruiting 8
Terminated 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Fosaprepitant

Sponsor Name

Sponsor Name for Fosaprepitant
Sponsor Trials
Merck Sharp & Dohme Corp. 14
National Cancer Institute (NCI) 5
M.D. Anderson Cancer Center 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Fosaprepitant
Sponsor Trials
Other 26
Industry 17
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Mallinckrodt
Moodys
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.